vs

Side-by-side financial comparison of OCTAVE SPECIALTY GROUP INC (OSG) and Phathom Pharmaceuticals, Inc. (PHAT). Click either name above to swap in a different company.

OCTAVE SPECIALTY GROUP INC is the larger business by last-quarter revenue ($66.9M vs $57.6M, roughly 1.2× Phathom Pharmaceuticals, Inc.). On growth, Phathom Pharmaceuticals, Inc. posted the faster year-over-year revenue change (94.1% vs 2.6%).

Octave Specialty Group Inc. is a specialty insurance holding company that provides tailored property and casualty insurance products. Its core business focuses on excess and surplus lines, catering to commercial and individual clients across primary North American markets with customized risk coverage solutions.

Phathom Pharmaceuticals is a clinical-stage biopharmaceutical firm focused on developing and commercializing innovative therapies for gastrointestinal diseases. Its lead product candidates address acid-related disorders, inflammatory bowel disease, and other GI conditions, serving patients mainly across North America and Europe.

OSG vs PHAT — Head-to-Head

Bigger by revenue
OSG
OSG
1.2× larger
OSG
$66.9M
$57.6M
PHAT
Growing faster (revenue YoY)
PHAT
PHAT
+91.5% gap
PHAT
94.1%
2.6%
OSG

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
OSG
OSG
PHAT
PHAT
Revenue
$66.9M
$57.6M
Net Profit
$-29.7M
Gross Margin
86.7%
Operating Margin
-76.7%
Net Margin
-73.8%
Revenue YoY
2.6%
94.1%
Net Profit YoY
-41.7%
71.6%
EPS (diluted)
$-0.82

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
OSG
OSG
PHAT
PHAT
Q4 25
$66.9M
$57.6M
Q3 25
$66.6M
$49.5M
Q2 25
$55.0M
$39.5M
Q1 25
$62.8M
$28.5M
Q4 24
$65.2M
$29.7M
Q3 24
$70.0M
$16.4M
Q2 24
$51.0M
$7.3M
Q1 24
$49.6M
Net Profit
OSG
OSG
PHAT
PHAT
Q4 25
$-29.7M
Q3 25
$-112.6M
$-30.0M
Q2 25
$-72.7M
$-75.8M
Q1 25
$-44.7M
$-94.3M
Q4 24
$-20.9M
Q3 24
$-27.5M
$-85.6M
Q2 24
$-750.0K
$-91.4M
Q1 24
$20.8M
Gross Margin
OSG
OSG
PHAT
PHAT
Q4 25
86.7%
Q3 25
87.5%
Q2 25
87.2%
Q1 25
86.9%
Q4 24
87.1%
Q3 24
85.6%
Q2 24
81.2%
Q1 24
Operating Margin
OSG
OSG
PHAT
PHAT
Q4 25
-76.7%
Q3 25
-48.2%
-30.8%
Q2 25
-41.8%
-151.7%
Q1 25
-24.1%
-276.5%
Q4 24
-55.5%
Q3 24
-29.7%
-433.0%
Q2 24
-28.9%
-1055.4%
Q1 24
-6.5%
Net Margin
OSG
OSG
PHAT
PHAT
Q4 25
-73.8%
Q3 25
-169.1%
-60.5%
Q2 25
-132.3%
-191.9%
Q1 25
-71.3%
-330.7%
Q4 24
-55.1%
Q3 24
-39.3%
-523.3%
Q2 24
-1.5%
-1248.6%
Q1 24
41.9%
EPS (diluted)
OSG
OSG
PHAT
PHAT
Q4 25
$-0.82
Q3 25
$-2.35
$-0.41
Q2 25
$-1.54
$-1.05
Q1 25
$-1.22
$-1.31
Q4 24
$-11.75
Q3 24
$-0.63
$-1.32
Q2 24
$-0.02
$-1.56
Q1 24
$0.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
OSG
OSG
PHAT
PHAT
Cash + ST InvestmentsLiquidity on hand
$146.4M
$130.0M
Total DebtLower is stronger
$117.6M
$209.1M
Stockholders' EquityBook value
$715.8M
$-438.2M
Total Assets
$2.2B
$259.1M
Debt / EquityLower = less leverage
0.16×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
OSG
OSG
PHAT
PHAT
Q4 25
$146.4M
$130.0M
Q3 25
$27.5M
$135.2M
Q2 25
$22.5M
$149.6M
Q1 25
$34.1M
$212.3M
Q4 24
$157.2M
$297.3M
Q3 24
$40.8M
$334.7M
Q2 24
$14.6M
$276.2M
Q1 24
$13.8M
Total Debt
OSG
OSG
PHAT
PHAT
Q4 25
$117.6M
$209.1M
Q3 25
$207.1M
Q2 25
$205.1M
Q1 25
$203.2M
Q4 24
$0
$201.4M
Q3 24
$518.0M
$175.7M
Q2 24
$515.0M
$174.4M
Q1 24
$512.0M
Stockholders' Equity
OSG
OSG
PHAT
PHAT
Q4 25
$715.8M
$-438.2M
Q3 25
$843.4M
$-422.5M
Q2 25
$859.8M
$-405.8M
Q1 25
$852.2M
$-338.4M
Q4 24
$798.4M
$-253.6M
Q3 24
$1.5B
$-187.1M
Q2 24
$1.4B
$-233.8M
Q1 24
$1.4B
Total Assets
OSG
OSG
PHAT
PHAT
Q4 25
$2.2B
$259.1M
Q3 25
$2.1B
$240.3M
Q2 25
$8.5B
$250.2M
Q1 25
$8.3B
$294.2M
Q4 24
$8.1B
$378.3M
Q3 24
$9.3B
$387.0M
Q2 24
$8.2B
$319.4M
Q1 24
$8.4B
Debt / Equity
OSG
OSG
PHAT
PHAT
Q4 25
0.16×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.35×
Q2 24
0.38×
Q1 24
0.38×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
OSG
OSG
PHAT
PHAT
Operating Cash FlowLast quarter
$-52.3M
$-166.8M
Free Cash FlowOCF − Capex
$-167.0M
FCF MarginFCF / Revenue
-290.0%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-328.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
OSG
OSG
PHAT
PHAT
Q4 25
$-52.3M
$-166.8M
Q3 25
$-41.2M
$-14.1M
Q2 25
$2.1M
$-62.7M
Q1 25
$-12.6M
$-84.9M
Q4 24
$762.0K
$-266.8M
Q3 24
$48.9M
$-63.6M
Q2 24
$20.4M
$-70.7M
Q1 24
$7.1M
Free Cash Flow
OSG
OSG
PHAT
PHAT
Q4 25
$-167.0M
Q3 25
$-14.1M
Q2 25
$-62.8M
Q1 25
$-84.9M
Q4 24
$-266.9M
Q3 24
$-63.6M
Q2 24
$-70.8M
Q1 24
FCF Margin
OSG
OSG
PHAT
PHAT
Q4 25
-290.0%
Q3 25
-28.6%
Q2 25
-159.0%
Q1 25
-297.9%
Q4 24
-899.8%
Q3 24
-389.0%
Q2 24
-966.2%
Q1 24
Capex Intensity
OSG
OSG
PHAT
PHAT
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.2%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.3%
Q2 24
0.6%
Q1 24
Cash Conversion
OSG
OSG
PHAT
PHAT
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.34×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

OSG
OSG

Other$28.7M43%
Specialty Property Casualty Program$23.1M34%
Accident Health$9.6M14%
Specialty Automobile$3.1M5%
Niche Specialty Risks$2.4M4%

PHAT
PHAT

Segment breakdown not available.

Related Comparisons